AbbVie Inc. $ABBV Shares Bought by Rede Wealth LLC

Rede Wealth LLC grew its stake in AbbVie Inc. (NYSE:ABBV) by 388.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,528 shares of the company’s stock after buying an additional 6,781 shares during the period. AbbVie accounts for 1.6% of Rede Wealth LLC’s investment portfolio, making the stock its 15th largest holding. Rede Wealth LLC’s holdings in AbbVie were worth $1,975,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Ellenbecker Investment Group increased its position in shares of AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after purchasing an additional 44 shares in the last quarter. Security National Bank of Sioux City Iowa IA boosted its position in shares of AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after purchasing an additional 45 shares during the period. Matthew Goff Investment Advisor LLC grew its stake in AbbVie by 0.3% during the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after buying an additional 45 shares during the last quarter. Willner & Heller LLC increased its position in AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock worth $1,759,000 after buying an additional 46 shares during the period. Finally, Hobart Private Capital LLC lifted its stake in AbbVie by 4.4% in the third quarter. Hobart Private Capital LLC now owns 1,127 shares of the company’s stock valued at $261,000 after buying an additional 48 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Down 1.8%

Shares of AbbVie stock opened at $220.06 on Friday. The company has a 50-day moving average of $226.59 and a two-hundred day moving average of $215.12. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The stock has a market cap of $388.93 billion, a PE ratio of 166.71, a price-to-earnings-growth ratio of 0.94 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is presently 496.97%.

Analyst Ratings Changes

A number of equities analysts have recently commented on ABBV shares. Wells Fargo & Company lifted their target price on shares of AbbVie from $240.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the company from $170.00 to $270.00 in a research note on Wednesday, September 17th. UBS Group started coverage on shares of AbbVie in a report on Wednesday. They issued a “neutral” rating and a $240.00 target price for the company. JPMorgan Chase & Co. raised their price target on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Finally, Piper Sandler restated an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple clinical and pipeline updates point to ongoing product-cycle growth (Phase 1 ABBV‑243 safety data, progress on icalcaprant, and completed real‑world studies for Rinvoq and upadacitinib), supporting longer‑term revenue diversification away from Humira. ABBV‑243 Phase 1 Trial
• Positive Sentiment: Zacks and other analysts highlight immunology momentum — strong Skyrizi and Rinvoq demand is expected to help offset Humira LOE, which is a constructive revenue thesis for FY‑2025/2026. Zacks: Immunology expectations
• Positive Sentiment: Dividend-focused coverage (Seeking Alpha pieces) and a recent buy rating from Berenberg support income‑oriented and value investors who view ABBV’s payout and yield as a stabilizer. Seeking Alpha: Dividend thesis Berenberg buy
• Neutral Sentiment: Press swirl about potential suitors for Revolution Medicines (reports that Merck may be in talks) creates market noise that can influence sector comps and M&A speculation but does not change AbbVie’s fundamentals unless a deal is announced. FT: Merck talks on Revolution
• Negative Sentiment: AbbVie publicly denied reports it was in talks to acquire Revolution Medicines after earlier speculation drove gains in both names; the denial removed the takeover premium and likely triggered short‑term selling pressure. Barron’s: AbbVie denies talks
• Negative Sentiment: Management’s updated Q4 and FY‑2025 EPS guidance came in at the low end or slightly below consensus (Q4: 3.320–3.360 vs. cons. 3.360; FY: 10.610–10.650 vs. cons. 10.650), which can cap near‑term upside and weigh on sentiment. (Company guidance update)
• Negative Sentiment: AbbVie flagged IPR&D and related expenses that will negatively impact Q4 EPS, a known near‑term earnings headwind highlighted by Seeking Alpha coverage. Seeking Alpha: IPR&D Q4 EPS impact

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.